Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment
- 72 Downloads
KeywordsBreast Cancer Trastuzumab Oncological Outcome Inflammatory Breast Cancer Breast Cancer Experience
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 3.Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–44.PubMedCrossRefGoogle Scholar
© Society of Surgical Oncology 2011